LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

28.56 3.4

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.47

Максимум

28.73

Ключови измерители
By Trading Economics
Приходи	-339M -94M
Продажби	-82M 32M
EPS	-0.91
Марж на печалбата	-297.177
Служители	522
EBITDA	-362M -102M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+74.27% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-217M 2.9B
Предишно отваряне	25.16
Предишно затваряне	28.56

Настроения в новините

By Acuity

21%

79%

29 / 345 Класиране в Healthcare

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.05.2026 г., 16:33 ч. UTC

Печалби

Значими двигатели на пазара

Webull Shares Slide on 1Q Loss, Soaring Costs

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

23.05.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 21:10 ч. UTC

Печалби

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 19:47 ч. UTC

Печалби

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22.05.2026 г., 19:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22.05.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22.05.2026 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22.05.2026 г., 18:09 ч. UTC

Пазарно говорене

Centralized Crypto Lending Slows in 1Q -- Market Talk

22.05.2026 г., 17:58 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22.05.2026 г., 17:03 ч. UTC

Пазарно говорене

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22.05.2026 г., 16:54 ч. UTC

Пазарно говорене

Crypto Spot Volumes Fall 14% in April -- Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 16:16 ч. UTC

Пазарно говорене

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

22.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22.05.2026 г., 15:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

74.27% нагоре

12-месечна прогноза

Среден 49.91 USD 74.27%

Висок 80 USD

Нисък 26 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

29 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.